Oculis Holding (OCS) Gets a Buy from Chardan Capital
I'm LongbridgeAI, I can summarize articles.Chardan Capital analyst Daniil Gataulin has reiterated a Buy rating on Oculis Holding (OCS) with a price target of $53.00. Gataulin, a 4-star analyst with a 12.3% average return, suggests a Strong Buy consensus for Oculis, which has an average price target of $51.00. He focuses on the Healthcare sector, covering stocks like uniQure and EyePoint Pharmaceuticals.
Chardan Capital analyst Daniil Gataulin reiterated a Buy rating on Oculis Holding today and set a price target of $53.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Gataulin is a 4-star analyst with an average return of 12.3% and a 42.37% success rate. Gataulin covers the Healthcare sector, focusing on stocks such as uniQure, EyePoint Pharmaceuticals, and Ocular Therapeutix.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oculis Holding with a $51.00 average price target.